Information on the total number of voting rights and shares
Rhea-AI Summary
Nyxoah (NASDAQ & Euronext: NYXH) reported updated capital and voting-rights figures following new shares issued on 20 February 2026. Share capital is EUR 6,511,048.19. Total securities and voting rights: 43,662,403 ordinary shares.
The company also disclosed 3,416,319 unissued subscription rights (excluding 462,677 issued-but-ungranted rights), 225 convertible bonds (nominal EUR 91,500 each) and a potential 4,117,500 voting rights upon conversion at EUR 5.00 per share.
Positive
- None.
Negative
- None.
News Market Reaction – NYXH
In the Feb 26 session, NYXH gained 5.62%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.0% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was exceptionally heavy at 6.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Middle East MoU | Positive | +8.7% | MoU to expand Genio therapy access and training in the Middle East. |
| Jan 21 | Capacity expansion | Positive | +1.1% | Investment in Belgian manufacturing facility to support global demand. |
| Jan 12 | Prelim 2025 results | Positive | -0.4% | Strong Q4 and FY2025 revenue growth and Q1 2026 guidance update. |
| Jan 12 | Transparency notice | Neutral | -0.4% | Disclosure of BNP Paribas Asset Management crossing 3% voting threshold. |
| Dec 29 | Conference presentation | Positive | +6.3% | Announcement of presentation at J.P. Morgan Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent operational and strategic announcements have often seen positive or modestly positive price reactions, with one divergence on strong preliminary earnings.
Over the last few months, Nyxoah reported several growth-oriented developments. On Dec 29, 2025, it highlighted a J.P. Morgan Healthcare Conference presentation, followed by a transparency notification about a 3.28% shareholder on Jan 12, 2026. That same day, preliminary Q4 and FY2025 results showed strong revenue growth and cash of €47.9M. In January and February 2026, Nyxoah announced Belgian manufacturing expansion and a Middle East MoU to broaden Genio access. Today’s disclosure focuses instead on updated share capital, voting rights, and potential dilution mechanisms.
Key Terms
voting rights financial
subscription rights financial
convertible bonds financial
nominal value financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
REGULATED INFORMATION
Information on the total number of voting rights and shares
Mont-Saint-Guibert (Belgium), February 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026.
- Share capital: EUR 6,511,048.19
- Total number of securities carrying voting rights: 43,662,403 (all ordinary shares)
- Total number of voting rights (= denominator): 43,662,403 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued: 3,416,319 (all granted subscription rights; this number excludes 462,677 subscription rights that were issued but not yet granted)
- Total number of convertible bonds: 225 convertible bonds with a nominal value of EUR 91,500 per bond
- Total number of voting rights that can be obtained in case of conversion of all 225 convertible bonds at the current conversion price of EUR 5.00 per share: 4,117,500
*
* *
Contact:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Attachment